(unaudited)
Financial performance in the six months ended June 30, 2009
(Comparative figures for the same period last year are shown in brackets)
- Sales growth continued in Q2 and organic growth in vaccine sales for H1 was
10%
- Revenue in H1 was DKK 927 million (871)
- Capacity costs dropped by 2% to DKK 588 million (598)
- Operating profit (EBIT) for H1 increased by 58% to DKK 71 million (45)
- Operating profit before depreciation and amortization (EBITDA) was DKK 110
million (86)
- Profit for the period was DKK 54 million (28)
Outlook for 2009 unchanged
For the 2009 financial year, ALK retains its forecast of organic growth in
allergy vaccine sales of 10% or more. The EBITDA forecast is retained at a
minimum of DKK 230 million, and the EBIT forecast is retained at a minimum of
DKK 140 million in 2009.
Hørsholm, August 18, 2009
ALK-Abelló A/S
Contact:
Jens Bager, President and CEO, tel +45 4574 7576.
ALK holds a conference call for analysts and investors today at 2.30 p.m. (CET)
at which Jens Bager, President and CEO, and Jutta of Rosenborg, CFO, will
review the results. Danish participants must call in on tel +45 7026 5040
before 2.25 p.m. (CET), and international participants must call in on tel +44
208 817 9301 before 2.25 p.m. (CET). The conference call will also be webcast
on our website: www.alk-abello.com, where the related presentation will be
available shortly before the conference call begins.
